nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—ABCB1—Dactinomycin—muscle cancer	0.0894	0.172	CbGbCtD
Loperamide—CYP2C8—Etoposide—muscle cancer	0.0745	0.143	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—muscle cancer	0.0671	0.129	CbGbCtD
Loperamide—ABCB1—Vincristine—muscle cancer	0.055	0.106	CbGbCtD
Loperamide—ABCB1—Etoposide—muscle cancer	0.0504	0.0969	CbGbCtD
Loperamide—ABCB1—Doxorubicin—muscle cancer	0.0344	0.0661	CbGbCtD
Loperamide—ABCB1—Methotrexate—muscle cancer	0.0333	0.064	CbGbCtD
Loperamide—CYP3A4—Vincristine—muscle cancer	0.033	0.0634	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—muscle cancer	0.0324	0.0623	CbGbCtD
Loperamide—CYP3A4—Etoposide—muscle cancer	0.0302	0.0581	CbGbCtD
Loperamide—Abdominal colic—Vincristine—muscle cancer	0.0275	0.132	CcSEcCtD
Loperamide—Megacolon toxic—Methotrexate—muscle cancer	0.0217	0.104	CcSEcCtD
Loperamide—CYP3A4—Doxorubicin—muscle cancer	0.0206	0.0396	CbGbCtD
Loperamide—Megacolon—Methotrexate—muscle cancer	0.011	0.0529	CcSEcCtD
Loperamide—Ileus paralytic—Vincristine—muscle cancer	0.00861	0.0413	CcSEcCtD
Loperamide—Altered state of consciousness—Vincristine—muscle cancer	0.00807	0.0387	CcSEcCtD
Loperamide—POMC—renal system—muscle cancer	0.00759	0.0703	CbGeAlD
Loperamide—Abdominal cramps—Vincristine—muscle cancer	0.00552	0.0265	CcSEcCtD
Loperamide—POMC—vagina—muscle cancer	0.0055	0.0509	CbGeAlD
Loperamide—Ileus—Vincristine—muscle cancer	0.00526	0.0253	CcSEcCtD
Loperamide—POMC—head—muscle cancer	0.00508	0.047	CbGeAlD
Loperamide—POMC—testis—muscle cancer	0.00491	0.0454	CbGeAlD
Loperamide—CACNA1A—head—muscle cancer	0.00485	0.0449	CbGeAlD
Loperamide—CACNA1A—testis—muscle cancer	0.00468	0.0434	CbGeAlD
Loperamide—OPRD1—renal system—muscle cancer	0.00419	0.0388	CbGeAlD
Loperamide—Bullous eruption—Doxorubicin—muscle cancer	0.00396	0.019	CcSEcCtD
Loperamide—OPRD1—head—muscle cancer	0.0028	0.0259	CbGeAlD
Loperamide—CALM3—smooth muscle tissue—muscle cancer	0.00274	0.0254	CbGeAlD
Loperamide—CALM2—embryo—muscle cancer	0.00274	0.0254	CbGeAlD
Loperamide—CALM1—embryo—muscle cancer	0.00273	0.0252	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.00272	0.0131	CcSEcCtD
Loperamide—OPRK1—head—muscle cancer	0.00269	0.0249	CbGeAlD
Loperamide—Urinary retention—Vincristine—muscle cancer	0.00257	0.0123	CcSEcCtD
Loperamide—CALM3—cardiac atrium—muscle cancer	0.00236	0.0219	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00231	0.0111	CcSEcCtD
Loperamide—Anaphylactoid reaction—Etoposide—muscle cancer	0.00226	0.0109	CcSEcCtD
Loperamide—Ileus—Doxorubicin—muscle cancer	0.00221	0.0106	CcSEcCtD
Loperamide—CALM2—smooth muscle tissue—muscle cancer	0.00215	0.0199	CbGeAlD
Loperamide—CALM1—smooth muscle tissue—muscle cancer	0.00214	0.0198	CbGeAlD
Loperamide—CALM2—renal system—muscle cancer	0.00207	0.0192	CbGeAlD
Loperamide—CALM1—renal system—muscle cancer	0.00206	0.0191	CbGeAlD
Loperamide—CALM3—tendon—muscle cancer	0.00206	0.0191	CbGeAlD
Loperamide—CALM3—bone marrow—muscle cancer	0.002	0.0185	CbGeAlD
Loperamide—Erythema multiforme—Dactinomycin—muscle cancer	0.00198	0.0095	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00197	0.00947	CcSEcCtD
Loperamide—CALM3—vagina—muscle cancer	0.00191	0.0177	CbGeAlD
Loperamide—OPRM1—head—muscle cancer	0.00191	0.0177	CbGeAlD
Loperamide—CALM2—cardiac atrium—muscle cancer	0.00186	0.0172	CbGeAlD
Loperamide—CALM1—cardiac atrium—muscle cancer	0.00185	0.0171	CbGeAlD
Loperamide—Urinary tract disorder—Vincristine—muscle cancer	0.00185	0.00887	CcSEcCtD
Loperamide—OPRM1—testis—muscle cancer	0.00185	0.0171	CbGeAlD
Loperamide—Urethral disorder—Vincristine—muscle cancer	0.00183	0.0088	CcSEcCtD
Loperamide—Depressed level of consciousness—Methotrexate—muscle cancer	0.00174	0.00838	CcSEcCtD
Loperamide—CYP2C8—renal system—muscle cancer	0.00172	0.0159	CbGeAlD
Loperamide—CALM3—testis—muscle cancer	0.00171	0.0158	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00167	0.00803	CcSEcCtD
Loperamide—CALM2—tendon—muscle cancer	0.00162	0.015	CbGeAlD
Loperamide—CALM1—tendon—muscle cancer	0.00161	0.0149	CbGeAlD
Loperamide—CALM2—bone marrow—muscle cancer	0.00157	0.0145	CbGeAlD
Loperamide—CALM1—bone marrow—muscle cancer	0.00156	0.0144	CbGeAlD
Loperamide—CYP2B6—renal system—muscle cancer	0.00154	0.0143	CbGeAlD
Loperamide—Discomfort—Dactinomycin—muscle cancer	0.00153	0.00736	CcSEcCtD
Loperamide—CALM2—vagina—muscle cancer	0.0015	0.0139	CbGeAlD
Loperamide—Urinary tract disorder—Etoposide—muscle cancer	0.0015	0.00718	CcSEcCtD
Loperamide—CALM1—vagina—muscle cancer	0.00149	0.0138	CbGeAlD
Loperamide—Urethral disorder—Etoposide—muscle cancer	0.00149	0.00713	CcSEcCtD
Loperamide—Erythema multiforme—Etoposide—muscle cancer	0.00143	0.00688	CcSEcCtD
Loperamide—CALM2—head—muscle cancer	0.00139	0.0128	CbGeAlD
Loperamide—CALM1—head—muscle cancer	0.00138	0.0128	CbGeAlD
Loperamide—Immune system disorder—Etoposide—muscle cancer	0.00137	0.00657	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—muscle cancer	0.00136	0.00651	CcSEcCtD
Loperamide—CALM2—testis—muscle cancer	0.00134	0.0124	CbGeAlD
Loperamide—CALM1—testis—muscle cancer	0.00133	0.0123	CbGeAlD
Loperamide—Anaphylactic shock—Vincristine—muscle cancer	0.00133	0.00638	CcSEcCtD
Loperamide—Nervous system disorder—Vincristine—muscle cancer	0.0013	0.00626	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—muscle cancer	0.00128	0.00616	CcSEcCtD
Loperamide—CYP2C8—vagina—muscle cancer	0.00124	0.0115	CbGeAlD
Loperamide—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00122	0.00584	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—muscle cancer	0.00119	0.00571	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00118	0.00567	CcSEcCtD
Loperamide—Abdominal pain—Dactinomycin—muscle cancer	0.00118	0.00564	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.00117	0.00563	CcSEcCtD
Loperamide—CYP3A4—renal system—muscle cancer	0.00116	0.0108	CbGeAlD
Loperamide—Loss of consciousness—Etoposide—muscle cancer	0.00116	0.00557	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vincristine—muscle cancer	0.00115	0.00551	CcSEcCtD
Loperamide—Fatigue—Vincristine—muscle cancer	0.00115	0.0055	CcSEcCtD
Loperamide—CYP2D6—renal system—muscle cancer	0.00115	0.0106	CbGeAlD
Loperamide—Constipation—Vincristine—muscle cancer	0.00114	0.00546	CcSEcCtD
Loperamide—CYP2B6—vagina—muscle cancer	0.00112	0.0103	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00112	0.00535	CcSEcCtD
Loperamide—CYP2C8—testis—muscle cancer	0.00111	0.0103	CbGeAlD
Loperamide—Discomfort—Etoposide—muscle cancer	0.00111	0.00533	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—muscle cancer	0.0011	0.00526	CcSEcCtD
Loperamide—ABCB1—embryo—muscle cancer	0.00109	0.0101	CbGeAlD
Loperamide—Gastrointestinal pain—Vincristine—muscle cancer	0.00109	0.00522	CcSEcCtD
Loperamide—Anaphylactic shock—Etoposide—muscle cancer	0.00108	0.00517	CcSEcCtD
Loperamide—Asthenia—Dactinomycin—muscle cancer	0.00107	0.00512	CcSEcCtD
Loperamide—Abdominal pain—Vincristine—muscle cancer	0.00105	0.00504	CcSEcCtD
Loperamide—Skin disorder—Etoposide—muscle cancer	0.00105	0.00502	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—muscle cancer	0.00104	0.00498	CcSEcCtD
Loperamide—CYP2B6—head—muscle cancer	0.00103	0.00955	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.00102	0.00491	CcSEcCtD
Loperamide—Diarrhoea—Dactinomycin—muscle cancer	0.00102	0.00489	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—muscle cancer	0.00101	0.00485	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.001	0.00481	CcSEcCtD
Loperamide—CYP2B6—testis—muscle cancer	0.000996	0.00922	CbGeAlD
Loperamide—Abdominal distension—Doxorubicin—muscle cancer	0.000988	0.00474	CcSEcCtD
Loperamide—Hypersensitivity—Vincristine—muscle cancer	0.000979	0.0047	CcSEcCtD
Loperamide—Somnolence—Etoposide—muscle cancer	0.000957	0.00459	CcSEcCtD
Loperamide—Asthenia—Vincristine—muscle cancer	0.000953	0.00458	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—muscle cancer	0.000946	0.00454	CcSEcCtD
Loperamide—Rash—Dactinomycin—muscle cancer	0.000938	0.0045	CcSEcCtD
Loperamide—Gastrointestinal disorder—Etoposide—muscle cancer	0.000929	0.00446	CcSEcCtD
Loperamide—Fatigue—Etoposide—muscle cancer	0.000928	0.00446	CcSEcCtD
Loperamide—Constipation—Etoposide—muscle cancer	0.00092	0.00442	CcSEcCtD
Loperamide—Diarrhoea—Vincristine—muscle cancer	0.000909	0.00436	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—muscle cancer	0.000896	0.0043	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—muscle cancer	0.00089	0.00427	CcSEcCtD
Loperamide—Nausea—Dactinomycin—muscle cancer	0.000883	0.00424	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—muscle cancer	0.00088	0.00423	CcSEcCtD
Loperamide—Dizziness—Vincristine—muscle cancer	0.000879	0.00422	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—muscle cancer	0.000875	0.0042	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000868	0.00417	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—muscle cancer	0.000858	0.00412	CcSEcCtD
Loperamide—Urticaria—Etoposide—muscle cancer	0.000855	0.00411	CcSEcCtD
Loperamide—Abdominal pain—Etoposide—muscle cancer	0.000851	0.00409	CcSEcCtD
Loperamide—Vomiting—Vincristine—muscle cancer	0.000845	0.00406	CcSEcCtD
Loperamide—Rash—Vincristine—muscle cancer	0.000838	0.00402	CcSEcCtD
Loperamide—Dermatitis—Vincristine—muscle cancer	0.000837	0.00402	CcSEcCtD
Loperamide—Headache—Vincristine—muscle cancer	0.000832	0.004	CcSEcCtD
Loperamide—ABCB1—renal system—muscle cancer	0.000824	0.00763	CbGeAlD
Loperamide—Immune system disorder—Methotrexate—muscle cancer	0.00082	0.00394	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—muscle cancer	0.000793	0.00381	CcSEcCtD
Loperamide—Nausea—Vincristine—muscle cancer	0.000789	0.00379	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—muscle cancer	0.000776	0.00373	CcSEcCtD
Loperamide—Asthenia—Etoposide—muscle cancer	0.000772	0.00371	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—muscle cancer	0.00077	0.0037	CcSEcCtD
Loperamide—CYP2D6—head—muscle cancer	0.000766	0.00709	CbGeAlD
Loperamide—Pruritus—Etoposide—muscle cancer	0.000761	0.00366	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—muscle cancer	0.000743	0.00357	CcSEcCtD
Loperamide—CYP2D6—testis—muscle cancer	0.00074	0.00685	CbGeAlD
Loperamide—Diarrhoea—Etoposide—muscle cancer	0.000736	0.00354	CcSEcCtD
Loperamide—Dizziness—Etoposide—muscle cancer	0.000712	0.00342	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—muscle cancer	0.00071	0.00341	CcSEcCtD
Loperamide—Vomiting—Etoposide—muscle cancer	0.000684	0.00329	CcSEcCtD
Loperamide—Rash—Etoposide—muscle cancer	0.000679	0.00326	CcSEcCtD
Loperamide—Dermatitis—Etoposide—muscle cancer	0.000678	0.00326	CcSEcCtD
Loperamide—Headache—Etoposide—muscle cancer	0.000674	0.00324	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—muscle cancer	0.000674	0.00324	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000668	0.00321	CcSEcCtD
Loperamide—Discomfort—Methotrexate—muscle cancer	0.000664	0.00319	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—muscle cancer	0.000645	0.0031	CcSEcCtD
Loperamide—Nausea—Etoposide—muscle cancer	0.000639	0.00307	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—muscle cancer	0.000632	0.00304	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—muscle cancer	0.000626	0.00301	CcSEcCtD
Loperamide—ABCB1—bone marrow—muscle cancer	0.000623	0.00577	CbGeAlD
Loperamide—Loss of consciousness—Doxorubicin—muscle cancer	0.000601	0.00289	CcSEcCtD
Loperamide—ABCB1—vagina—muscle cancer	0.000597	0.00552	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000578	0.00278	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—muscle cancer	0.000575	0.00276	CcSEcCtD
Loperamide—Somnolence—Methotrexate—muscle cancer	0.000573	0.00275	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—muscle cancer	0.00057	0.00273	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—muscle cancer	0.000567	0.00272	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—muscle cancer	0.000558	0.00268	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000557	0.00267	CcSEcCtD
Loperamide—Fatigue—Methotrexate—muscle cancer	0.000556	0.00267	CcSEcCtD
Loperamide—ABCB1—head—muscle cancer	0.000551	0.0051	CbGeAlD
Loperamide—Nervous system disorder—Doxorubicin—muscle cancer	0.000547	0.00263	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—muscle cancer	0.000542	0.0026	CcSEcCtD
Loperamide—ABCB1—testis—muscle cancer	0.000532	0.00493	CbGeAlD
Loperamide—Gastrointestinal pain—Methotrexate—muscle cancer	0.000527	0.00253	CcSEcCtD
Loperamide—Urticaria—Methotrexate—muscle cancer	0.000512	0.00246	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—muscle cancer	0.00051	0.00245	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—muscle cancer	0.000496	0.00238	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—muscle cancer	0.000491	0.00236	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000482	0.00231	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—muscle cancer	0.000481	0.00231	CcSEcCtD
Loperamide—Constipation—Doxorubicin—muscle cancer	0.000477	0.00229	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—muscle cancer	0.000475	0.00228	CcSEcCtD
Loperamide—Asthenia—Methotrexate—muscle cancer	0.000463	0.00222	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000456	0.00219	CcSEcCtD
Loperamide—Pruritus—Methotrexate—muscle cancer	0.000456	0.00219	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—muscle cancer	0.000443	0.00213	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—muscle cancer	0.000441	0.00212	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—muscle cancer	0.000441	0.00212	CcSEcCtD
Loperamide—Dizziness—Methotrexate—muscle cancer	0.000426	0.00205	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—muscle cancer	0.000411	0.00197	CcSEcCtD
Loperamide—Vomiting—Methotrexate—muscle cancer	0.00041	0.00197	CcSEcCtD
Loperamide—Rash—Methotrexate—muscle cancer	0.000406	0.00195	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—muscle cancer	0.000406	0.00195	CcSEcCtD
Loperamide—Headache—Methotrexate—muscle cancer	0.000404	0.00194	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—muscle cancer	0.000401	0.00192	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—muscle cancer	0.000395	0.0019	CcSEcCtD
Loperamide—Nausea—Methotrexate—muscle cancer	0.000383	0.00184	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—muscle cancer	0.000382	0.00183	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—muscle cancer	0.000369	0.00177	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—muscle cancer	0.000355	0.0017	CcSEcCtD
Loperamide—Rash—Doxorubicin—muscle cancer	0.000352	0.00169	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—muscle cancer	0.000352	0.00169	CcSEcCtD
Loperamide—Headache—Doxorubicin—muscle cancer	0.00035	0.00168	CcSEcCtD
Loperamide—Nausea—Doxorubicin—muscle cancer	0.000332	0.00159	CcSEcCtD
Loperamide—CALM1—B Cell Activation—KIT—muscle cancer	0.000185	0.00113	CbGpPWpGaD
Loperamide—CALM3—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000185	0.00113	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—FOXO1—muscle cancer	0.000185	0.00113	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000183	0.00112	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000181	0.00111	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000181	0.00111	CbGpPWpGaD
Loperamide—CALM2—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000179	0.00109	CbGpPWpGaD
Loperamide—CALM1—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000179	0.00109	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—FOXO1—muscle cancer	0.000179	0.00109	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—FOXO1—muscle cancer	0.000179	0.00109	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—VEGFA—muscle cancer	0.000179	0.00109	CbGpPWpGaD
Loperamide—CALM3—Alzheimers Disease—TP53—muscle cancer	0.000178	0.00109	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000177	0.00108	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000177	0.00108	CbGpPWpGaD
Loperamide—CALM3—Downstream signal transduction—MDM2—muscle cancer	0.000176	0.00107	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR—MDM2—muscle cancer	0.000175	0.00107	CbGpPWpGaD
Loperamide—CALM3—Signaling by VEGF—VEGFA—muscle cancer	0.000174	0.00107	CbGpPWpGaD
Loperamide—CALM3—Signaling by ERBB2—MDM2—muscle cancer	0.000174	0.00106	CbGpPWpGaD
Loperamide—CALM3—DAP12 signaling—MDM2—muscle cancer	0.000173	0.00106	CbGpPWpGaD
Loperamide—CALM1—Alzheimers Disease—TP53—muscle cancer	0.000172	0.00105	CbGpPWpGaD
Loperamide—CALM2—Alzheimers Disease—TP53—muscle cancer	0.000172	0.00105	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—PTCH1—muscle cancer	0.000171	0.00105	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—CNR1—muscle cancer	0.000171	0.00104	CbGpPWpGaD
Loperamide—CALM1—Downstream signal transduction—MDM2—muscle cancer	0.00017	0.00104	CbGpPWpGaD
Loperamide—CALM2—Downstream signal transduction—MDM2—muscle cancer	0.00017	0.00104	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR—MDM2—muscle cancer	0.000169	0.00103	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR—MDM2—muscle cancer	0.000169	0.00103	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000169	0.00103	CbGpPWpGaD
Loperamide—CALM1—Signaling by VEGF—VEGFA—muscle cancer	0.000169	0.00103	CbGpPWpGaD
Loperamide—CALM2—Signaling by VEGF—VEGFA—muscle cancer	0.000169	0.00103	CbGpPWpGaD
Loperamide—CALM2—Signaling by ERBB2—MDM2—muscle cancer	0.000168	0.00103	CbGpPWpGaD
Loperamide—CALM1—Signaling by ERBB2—MDM2—muscle cancer	0.000168	0.00103	CbGpPWpGaD
Loperamide—CALM2—DAP12 signaling—MDM2—muscle cancer	0.000167	0.00102	CbGpPWpGaD
Loperamide—CALM1—DAP12 signaling—MDM2—muscle cancer	0.000167	0.00102	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—KIT—muscle cancer	0.000166	0.00102	CbGpPWpGaD
Loperamide—CALM3—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000163	0.000996	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR in disease—MDM2—muscle cancer	0.000163	0.000996	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—MDM2—muscle cancer	0.000163	0.000996	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR—MDM2—muscle cancer	0.000161	0.000987	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.00016	0.000979	CbGpPWpGaD
Loperamide—CALM3—Signaling by PDGF—MDM2—muscle cancer	0.000159	0.000974	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—CNR1—muscle cancer	0.000159	0.000972	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KIDINS220—muscle cancer	0.000159	0.000972	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000157	0.000964	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—MDM2—muscle cancer	0.000157	0.000964	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—MDM2—muscle cancer	0.000157	0.000964	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—MDM2—muscle cancer	0.000157	0.000964	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR in disease—MDM2—muscle cancer	0.000157	0.000964	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000157	0.000964	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—FH—muscle cancer	0.000157	0.000962	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—MDM2—muscle cancer	0.000156	0.000955	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—MDM2—muscle cancer	0.000156	0.000955	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000155	0.000947	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000155	0.000947	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—MDM2—muscle cancer	0.000154	0.000943	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—MDM2—muscle cancer	0.000154	0.000943	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KIDINS220—muscle cancer	0.000153	0.00094	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KIDINS220—muscle cancer	0.000153	0.00094	CbGpPWpGaD
Loperamide—CALM3—Metabolism—FH—muscle cancer	0.000153	0.000937	CbGpPWpGaD
Loperamide—POMC—Metabolism—PTGS2—muscle cancer	0.000151	0.000923	CbGpPWpGaD
Loperamide—CALM3—B Cell Activation—MDM2—muscle cancer	0.000151	0.000922	CbGpPWpGaD
Loperamide—CALM1—Metabolism—FH—muscle cancer	0.000148	0.000906	CbGpPWpGaD
Loperamide—CALM2—Metabolism—FH—muscle cancer	0.000148	0.000906	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000148	0.000904	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—MDM2—muscle cancer	0.000146	0.000892	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—MDM2—muscle cancer	0.000146	0.000892	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CNR1—muscle cancer	0.000144	0.000883	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000144	0.000882	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000143	0.000874	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000143	0.000874	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—FOXO4—muscle cancer	0.000143	0.000873	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—KIT—muscle cancer	0.000141	0.000862	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000139	0.000854	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000139	0.000854	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—FOXO4—muscle cancer	0.000138	0.000845	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—FOXO4—muscle cancer	0.000138	0.000845	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—FOXO4—muscle cancer	0.000137	0.000839	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PTCH1—muscle cancer	0.000136	0.000834	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—KIT—muscle cancer	0.000136	0.000834	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—KIT—muscle cancer	0.000136	0.000834	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—FH—muscle cancer	0.000133	0.000815	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—FOXO4—muscle cancer	0.000132	0.000811	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—FOXO4—muscle cancer	0.000132	0.000811	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—MDM2—muscle cancer	0.000131	0.000801	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—PTGS2—muscle cancer	0.00013	0.000798	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—IGF2—muscle cancer	0.000127	0.000779	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—IGF2—muscle cancer	0.000123	0.000753	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—IGF2—muscle cancer	0.000123	0.000753	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD34—muscle cancer	0.000122	0.000748	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PTCH1—muscle cancer	0.000119	0.000731	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD34—muscle cancer	0.000118	0.000724	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD34—muscle cancer	0.000118	0.000724	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—FOXO4—muscle cancer	0.000117	0.000717	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000116	0.00071	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—FH—muscle cancer	0.000116	0.00071	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CNR1—muscle cancer	0.000115	0.000704	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—MDM2—muscle cancer	0.000113	0.000692	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000112	0.000685	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—MDM2—muscle cancer	0.000111	0.000679	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—MDM2—muscle cancer	0.000109	0.00067	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—MDM2—muscle cancer	0.000109	0.00067	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—FH—muscle cancer	0.000109	0.000669	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—MDM2—muscle cancer	0.000107	0.000657	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—MDM2—muscle cancer	0.000107	0.000657	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PTCH1—muscle cancer	0.000106	0.000647	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—FOXO1—muscle cancer	0.000105	0.000645	CbGpPWpGaD
Loperamide—CALM3—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.000103	0.000633	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—FOXO4—muscle cancer	0.000103	0.000629	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PTCH1—muscle cancer	0.000102	0.000626	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PTCH1—muscle cancer	0.000102	0.000626	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—FOXO1—muscle cancer	0.000102	0.000624	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—FOXO1—muscle cancer	0.000102	0.000624	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—FOXO1—muscle cancer	0.000101	0.000619	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PTCH1—muscle cancer	0.000101	0.000618	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CNR1—muscle cancer	0.000101	0.000617	CbGpPWpGaD
Loperamide—CALM2—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.0001	0.000613	CbGpPWpGaD
Loperamide—CALM1—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.0001	0.000613	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—VEGFA—muscle cancer	9.93e-05	0.000608	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—FOXO1—muscle cancer	9.79e-05	0.000599	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—FOXO1—muscle cancer	9.79e-05	0.000599	CbGpPWpGaD
Loperamide—CALM3—Disease—ENO2—muscle cancer	9.41e-05	0.000576	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IGF2—muscle cancer	9.4e-05	0.000575	CbGpPWpGaD
Loperamide—CALM1—Disease—ENO2—muscle cancer	9.1e-05	0.000557	CbGpPWpGaD
Loperamide—CALM2—Disease—ENO2—muscle cancer	9.1e-05	0.000557	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CNR1—muscle cancer	8.93e-05	0.000547	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—MED12—muscle cancer	8.88e-05	0.000544	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	8.81e-05	0.000539	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—FOXO4—muscle cancer	8.68e-05	0.000531	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—FOXO1—muscle cancer	8.65e-05	0.00053	CbGpPWpGaD
Loperamide—CALM3—Metabolism—MED12—muscle cancer	8.64e-05	0.000529	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CNR1—muscle cancer	8.63e-05	0.000529	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CNR1—muscle cancer	8.63e-05	0.000529	CbGpPWpGaD
Loperamide—CALM3—Disease—HMGA1—muscle cancer	8.55e-05	0.000524	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CNR1—muscle cancer	8.52e-05	0.000522	CbGpPWpGaD
Loperamide—CALM1—Metabolism—MED12—muscle cancer	8.36e-05	0.000512	CbGpPWpGaD
Loperamide—CALM2—Metabolism—MED12—muscle cancer	8.36e-05	0.000512	CbGpPWpGaD
Loperamide—CALM3—Immune System—FOXO4—muscle cancer	8.31e-05	0.000509	CbGpPWpGaD
Loperamide—CALM2—Disease—HMGA1—muscle cancer	8.27e-05	0.000507	CbGpPWpGaD
Loperamide—CALM1—Disease—HMGA1—muscle cancer	8.27e-05	0.000507	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IGF2—muscle cancer	8.24e-05	0.000505	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ENO2—muscle cancer	8.1e-05	0.000496	CbGpPWpGaD
Loperamide—CALM2—Immune System—FOXO4—muscle cancer	8.04e-05	0.000492	CbGpPWpGaD
Loperamide—CALM1—Immune System—FOXO4—muscle cancer	8.04e-05	0.000492	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KIT—muscle cancer	8.03e-05	0.000492	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ENO2—muscle cancer	7.88e-05	0.000483	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KIT—muscle cancer	7.76e-05	0.000475	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KIT—muscle cancer	7.76e-05	0.000475	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KIT—muscle cancer	7.71e-05	0.000472	CbGpPWpGaD
Loperamide—CALM3—Disease—FOXO4—muscle cancer	7.67e-05	0.00047	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ENO2—muscle cancer	7.62e-05	0.000467	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ENO2—muscle cancer	7.62e-05	0.000467	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—FOXO1—muscle cancer	7.58e-05	0.000464	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—MED12—muscle cancer	7.52e-05	0.00046	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TP53—muscle cancer	7.5e-05	0.000459	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KIT—muscle cancer	7.46e-05	0.000457	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KIT—muscle cancer	7.46e-05	0.000457	CbGpPWpGaD
Loperamide—CALM1—Disease—FOXO4—muscle cancer	7.42e-05	0.000454	CbGpPWpGaD
Loperamide—CALM2—Disease—FOXO4—muscle cancer	7.42e-05	0.000454	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—FH—muscle cancer	7.14e-05	0.000437	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IGF2—muscle cancer	6.96e-05	0.000426	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ENO2—muscle cancer	6.85e-05	0.00042	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.66e-05	0.000408	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KIT—muscle cancer	6.59e-05	0.000403	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MED12—muscle cancer	6.55e-05	0.000401	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—FOXO1—muscle cancer	6.41e-05	0.000392	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—MDM2—muscle cancer	6.32e-05	0.000387	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTCH1—muscle cancer	6.25e-05	0.000382	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MED12—muscle cancer	6.17e-05	0.000378	CbGpPWpGaD
Loperamide—CALM3—Immune System—FOXO1—muscle cancer	6.14e-05	0.000376	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—MDM2—muscle cancer	6.12e-05	0.000374	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—MDM2—muscle cancer	6.12e-05	0.000374	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—MDM2—muscle cancer	6.07e-05	0.000372	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTCH1—muscle cancer	6.04e-05	0.00037	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTCH1—muscle cancer	6.04e-05	0.00037	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ENO2—muscle cancer	5.97e-05	0.000366	CbGpPWpGaD
Loperamide—CALM2—Immune System—FOXO1—muscle cancer	5.94e-05	0.000363	CbGpPWpGaD
Loperamide—CALM1—Immune System—FOXO1—muscle cancer	5.94e-05	0.000363	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—MDM2—muscle cancer	5.87e-05	0.00036	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—MDM2—muscle cancer	5.87e-05	0.00036	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KIT—muscle cancer	5.78e-05	0.000354	CbGpPWpGaD
Loperamide—CALM3—Disease—FOXO1—muscle cancer	5.66e-05	0.000347	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ENO2—muscle cancer	5.63e-05	0.000345	CbGpPWpGaD
Loperamide—CALM2—Disease—FOXO1—muscle cancer	5.48e-05	0.000336	CbGpPWpGaD
Loperamide—CALM1—Disease—FOXO1—muscle cancer	5.48e-05	0.000336	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FOXO4—muscle cancer	5.37e-05	0.000329	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.36e-05	0.000328	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—VEGFA—muscle cancer	5.33e-05	0.000327	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CNR1—muscle cancer	5.27e-05	0.000323	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FOXO4—muscle cancer	5.2e-05	0.000318	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FOXO4—muscle cancer	5.2e-05	0.000318	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MDM2—muscle cancer	5.19e-05	0.000318	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—VEGFA—muscle cancer	5.16e-05	0.000316	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—VEGFA—muscle cancer	5.16e-05	0.000316	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CNR1—muscle cancer	5.1e-05	0.000312	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CNR1—muscle cancer	5.1e-05	0.000312	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KIT—muscle cancer	4.88e-05	0.000299	CbGpPWpGaD
Loperamide—CALM3—Immune System—KIT—muscle cancer	4.68e-05	0.000286	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MDM2—muscle cancer	4.55e-05	0.000279	CbGpPWpGaD
Loperamide—CALM2—Immune System—KIT—muscle cancer	4.52e-05	0.000277	CbGpPWpGaD
Loperamide—CALM1—Immune System—KIT—muscle cancer	4.52e-05	0.000277	CbGpPWpGaD
Loperamide—CALM3—Disease—KIT—muscle cancer	4.32e-05	0.000264	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF2—muscle cancer	4.31e-05	0.000264	CbGpPWpGaD
Loperamide—CALM2—Disease—KIT—muscle cancer	4.18e-05	0.000256	CbGpPWpGaD
Loperamide—CALM1—Disease—KIT—muscle cancer	4.18e-05	0.000256	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF2—muscle cancer	4.17e-05	0.000255	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF2—muscle cancer	4.17e-05	0.000255	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MED12—muscle cancer	4.04e-05	0.000247	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—muscle cancer	4.03e-05	0.000247	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FOXO1—muscle cancer	3.97e-05	0.000243	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—VEGFA—muscle cancer	3.94e-05	0.000241	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—muscle cancer	3.9e-05	0.000239	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—muscle cancer	3.9e-05	0.000239	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MDM2—muscle cancer	3.85e-05	0.000235	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FOXO1—muscle cancer	3.84e-05	0.000235	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FOXO1—muscle cancer	3.84e-05	0.000235	CbGpPWpGaD
Loperamide—CALM3—Immune System—MDM2—muscle cancer	3.68e-05	0.000225	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ENO2—muscle cancer	3.68e-05	0.000225	CbGpPWpGaD
Loperamide—CALM2—Immune System—MDM2—muscle cancer	3.56e-05	0.000218	CbGpPWpGaD
Loperamide—CALM1—Immune System—MDM2—muscle cancer	3.56e-05	0.000218	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—muscle cancer	3.46e-05	0.000212	CbGpPWpGaD
Loperamide—CALM3—Disease—MDM2—muscle cancer	3.4e-05	0.000208	CbGpPWpGaD
Loperamide—CALM1—Disease—MDM2—muscle cancer	3.29e-05	0.000201	CbGpPWpGaD
Loperamide—CALM2—Disease—MDM2—muscle cancer	3.29e-05	0.000201	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—muscle cancer	3.28e-05	0.000201	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—muscle cancer	3.17e-05	0.000194	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—muscle cancer	3.17e-05	0.000194	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KIT—muscle cancer	3.02e-05	0.000185	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—muscle cancer	2.98e-05	0.000182	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KIT—muscle cancer	2.92e-05	0.000179	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KIT—muscle cancer	2.92e-05	0.000179	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—muscle cancer	2.92e-05	0.000179	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—muscle cancer	2.82e-05	0.000173	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—muscle cancer	2.74e-05	0.000168	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—muscle cancer	2.65e-05	0.000163	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—muscle cancer	2.65e-05	0.000163	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—muscle cancer	2.61e-05	0.00016	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—muscle cancer	2.39e-05	0.000146	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MDM2—muscle cancer	2.38e-05	0.000146	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MDM2—muscle cancer	2.3e-05	0.000141	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MDM2—muscle cancer	2.3e-05	0.000141	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—muscle cancer	2.21e-05	0.000135	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—muscle cancer	2.08e-05	0.000127	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—muscle cancer	1.96e-05	0.00012	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—muscle cancer	1.81e-05	0.000111	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—muscle cancer	1.75e-05	0.000107	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—muscle cancer	1.75e-05	0.000107	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—muscle cancer	1.37e-05	8.36e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—muscle cancer	1.32e-05	8.09e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—muscle cancer	1.32e-05	8.09e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—muscle cancer	1.28e-05	7.85e-05	CbGpPWpGaD
